Get reliable RNA-Seq data from minimal RNA input while preserving precious samples.
Discovery’s Genomics RNA-Seq workflows can be tailored for your specific needs
Delivers High Precision, Accuracy, Sensitivity, and Specificity with Minimal Sample Utilization
~94% success rate compared to ~40% with other standard off-the-shelf methods
Low-Input RNA Sequencing Pipeline Optimized to Minimize Sample Utilization Technical Notes
Figure 1. (A) Assessing Discovery’s dual nucleic acid extraction method on FFPE across many indications shows a significant improvement in RNA quality. (B) This enhanced method ultimately resulted in the immediate improvement of RNA-Seq success rate of sequencing with at least 100M PE reads per sample and a mapping rate > 85% by nearly 200%.
RNA-Seq detects gene fusions and differential expression of disease-causing transcripts, serving as a powerful tool for molecular profiling in clinical trials. Discovery Genomics’ optimized workflows and CAP-accredited, CLIA-certified, and GCLP-compliant laboratory accelerate clinical trial success, aiding in the discovery of potential predictive biomarkers for companion diagnostic development.
Chaudhary R, et al. Long noncoding RNA, LINC00460, as a prognostic biomarker in head and neck squamous cell carcinoma (HNSCC). Am J Transl Res. 2020; 12(2): 684–696. PMCID: PMC7061833.
Dai C, et al. Tacrolimus- and sirolimus-induced human β cell dysfunction is reversible and preventable. JCI Insight. 2020 Jan 16; 5(1): e130770. PMCID: PMC7030815.
Fish EJ, et al. Circulating microRNA as biomarkers of canine mammary carcinoma in dogs. J Vet Intern Med. 2020 May; 34(3): 1282–1290. PMCID: PMC7255679.
Barnhill EC, et al. Characterization of novel small RNAs (sRNAs) contributing to the desiccation response of Salmonella enterica serovar Typhimurium. RNA Biol. 2019 Nov;16(11):1643-1657. doi: 10.1080/15476286.2019.1653680.
Contact us at info@dls.com or click here and we will put you in touch with the right experts to discuss your project.
An Analytical Plan will be compiled by your dedicated project manager. The Analytical Plan details laboratory activities and ensures client alignment prior to any sample processing.
The Analytical Plan will be shared with you for edits and comments. Discovery’s quality standards require that the Analytical Plan is agreed upon and signed off by Discovery and the client prior to any testing being performed.
Your primary contact throughout your project will be your dedicated project manager.
NOTE: Some projects may not require a formal Analytical Plan if deemed out of scope for the nature of the project at Discovery's discretion. This will be discussed with your Project Manager during the initiation of each project.
All sample shipments will require a clearly defined manifest including Protocol/Study identification, sample information, patient ID (if available), and contact information for shipper to rectify missing and/or ambiguous information.
Click here to see sample shipment requirements.
Any shipments missing this critical information will be put into quarantine and may experience extended turnaround times.
Join Discovery Life Sciences at Phacilitate's Advanced Therapies Week 2025, Jan 20-23 in Dallas! Visit us at Booth 161 and join Dr. Yuki Maves' presentation on Jan 23. Supply Chain: […]
Join Discovery at Precision Medicine Tri-Con 2025.
Join Discovery at World CB & CDx Summit Europe 2025.
Copyright © 2024 Discovery Life Sciences. All rights reserved.
Designed & Developed by Altitude Marketing
